SGCB and sickle cell disease: Similarly, olinciguat, another sGC stimulator, was shown to reduce inflammation, vaso-occlusion, and nephropathy in a murine model for sickle cell anemia, highlighting the therapeutic potential of these compounds (Tchernychev et al., 2021).